info@oncologyventure.com

First Patient Dosed in Phase 2 Study of PARP/Tankyrase Inhibitor 2X-121 for Metastatic Breast Cancer

CAMBRIDGE, Mass. and HOERSHOLM, Denmark, June 26, 2018 — Oncology Venture US Inc., Oncology Venture AB (OV:ST) (“OV”) and Medical...

2X Oncology Announces Validation of Drug Response Predictor (DRP) for its PARP Inhibitor 2X-121

— Developed DRP Successfully Identified Responders and Non-responders to Treatment with 2X-121 in 13-Patient Blinded Study —  Cambridge, MA – August...